Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.05
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.22 -5.93%
Revenue Growth %: -49.8%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Revenue Growth %: -49.8%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.05), versus ($0.07) reported last year.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
